

CAR-T therapy works — So why can't all patients access it?



Early hospital-level insights from the
EASYGEN Consortium



The Access Gap

Despite major clinical success,
many eligible patients
still do not receive CAR-T therapy.

The reason is **not medicine**
—
it's **system friction.**

Inside a Certified CAR-T Center



An in-depth evaluation of a certified German CAR-T hospital revealed **interlocking barriers**, including:

- Complex interdependency between eligibility & reimbursement
- Fragmented logistics & documentation workload
- High coordination effort with little digital support

Access fails through cumulative friction, not single bottlenecks.

Unlocking Access



- Digital coordination workflows
- Local apheresis & cryostorage capacity
- Standardised bridging protocols
- Harmonised certification & interoperable data

**System design matters as
much as innovation**

From Innovation to Access

EASYGEN aims to enable rapid & non-viral decentralized CAR-T manufacturing to make advanced therapies more accessible and scalable.

👉 Interested in contributing your expertise and to participate in structured HCP questionnaires to outline and understanding major barriers across Europe?

Send us a DM - we'd love to hear from you.

👉 For more information about EASYGEN, visit CORDIS:



EASYGEN is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101194710.

The JU receives support from the European Union's Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bio, MedTech Europe, and Vaccines Europe.



Co-funded by
the European Union